Press Release: Novartis data at ASH and SABCS -2-

of biosimilar filgrastim-sndz over reference filgrastim among breast

cancer patients: a simulation model analysis [Abstract #675; Friday,

December 7, 5:00 PM CT]

Throughout the 2018 ASH Annual Meeting and SABCS Annual Symposium,

Novartis will host dedicated content on

https://www.novartis.com/our-focus/cancer that will feature unique

insights and perspectives on emerging areas of cancer care and research.

Product Information

Approved indications for products vary by country and not all

indications are available in every country. The product safety and

efficacy profiles have not yet been established outside the approved

indications. Because of the uncertainty of clinical trials, there is no

guarantee that compounds will become commercially available with

additional indications.

For full prescribing information, including approved indications and

important safety information about marketed products, please visit

https://www.novartis.com/our-company/global-product-portfolio.

Asciminib (ABL001), crizanlizumab (SEG101), alpelisib (BYL719) and

LSZ102 are investigational compounds. Efficacy and safety have not been

established. There is no guarantee these compounds will become

commercially available.

Disclaimer

This press release contains forward-looking statements within the

meaning of the United States Private Securities Litigation Reform Act of

1995. Forward-looking statements can generally be identified by words

such as "potential," "can," "will," "plan," "expect," "anticipate,"

"look forward," "believe," "committed," "investigational," "pipeline,"

"launch," or similar terms, or by express or implied discussions

regarding potential marketing approvals, new indications or labeling for

the investigational or approved products described in this press release,

or regarding potential future revenues from such products. You should

not place undue reliance on these statements. Such forward-looking

statements are based on our current beliefs and expectations regarding

future events, and are subject to significant known and unknown risks

and uncertainties. Should one or more of these risks or uncertainties

materialize, or should underlying assumptions prove incorrect, actual

results may vary materially from those set forth in the forward-looking

statements. There can be no guarantee that the investigational or

approved products described in this press release will be submitted or

approved for sale or for any additional indications or labeling in any

market, or at any particular time. Nor can there be any guarantee that

such products will be commercially successful in the future. In

particular, our expectations regarding such products could be affected

by, among other things, the uncertainties inherent in research and

development, including clinical trial results and additional analysis of

existing clinical data; regulatory actions or delays or government

regulation generally; global trends toward health care cost containment,

including government, payor and general public pricing and reimbursement

pressures; our ability to obtain or maintain proprietary intellectual

property protection; the particular prescribing preferences of

physicians and patients; general political and economic conditions;

safety, quality or manufacturing issues; potential or actual data

security and data privacy breaches, or disruptions of our information

technology systems, and other risks and factors referred to in Novartis

AG's current Form 20-F on file with the US Securities and Exchange

Commission. Novartis is providing the information in this press release

as of this date and does not undertake any obligation to update any

forward-looking statements contained in this press release as a result

of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach nearly 1 billion people globally

and we are finding innovative ways to expand access to our latest

treatments. About 125,000 people of more than 140 nationalities work at

Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

http://twitter.com/novartis

For Novartis multimedia content, please visit

www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

*Novartis and the University of Pennsylvania's Perelman School of

Medicine (Penn) have a global collaboration to research, develop and

commercialize chimeric antigen receptor T cell (CAR-T) therapies for the

investigational treatment of cancers.

**Jakavi is a registered trademark of Novartis AG in countries outside

the United States. Jakafi is a registered trademark of Incyte

Corporation. Novartis licensed ruxolitinib from Incyte Corporation for

development and commercialization outside the United States.

***Kisqali was developed by the Novartis Institutes for BioMedical

Research (NIBR) under a research collaboration with Astex

Pharmaceuticals.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Eric Althoff Julie Masow

Novartis Global Media Relations Novartis Oncology Media Relations

+41 61 324 7999 (direct) +1 862 579 8456 (mobile)

+41 79 593 4202 (mobile) julie.masow@novartis.com

eric.althoff@novartis.com Michelle Bauman

Sandoz Global Communications

+1 973 714 8043 (mobile)

michelle.bauman@sandoz.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2223808/871561.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

November 02, 2018 17:15 ET (21:15 GMT)